Enable Patient Support
through Hizentra Connect℠
Comprehensive support from the start
Hizentra Connect is a suite of support programs and resources to optimize your patient’s experience and provide ongoing support throughout their journey.
To get the guidance and support you need:
Call 1-877-355-4447 Monday-Friday, 8 AM to 8 PM ET.
Financial support
Copay Support
The Copay Support Program helps eligible people with commercial insurance by assisting with out-of-pocket expenses for Hizentra.
Most people with commercial insurance pay $0 out of pocket.*
- Hizentra Copay Program provides eligible patients with commercial insurance up to $20,000 in copay assistance per calendar year
Free Trial
To help your patients determine if Hizentra is right for them, they may be eligible for a 1-month supply of medicine, infusion equipment, and nurse training for free.
A free trial is a great way to help prevent lapses in treatment when switching patients.
*Subject to terms and conditions of the Copay Support Program, available here.
Insurance navigation support
97% of CIDP patients with commercial insurance are covered.1† Hizentra Connect will assist patients with any insurance questions they may have so their insurance processes can go as smoothly as possible.
Ready to Connect?
Reimbursement support involves prior authorizations, appeals, and connection to CSL Behring’s field reimbursement team, who will work with your office.
Uninsured or Underinsured Patients?
The Patient Assistance Program helps qualified patients get the treatment they need.
Patients With a Lapse in Coverage?
Patients may continue to receive Hizentra in the event of a lapse in third-party private health insurance.‡
†As of July 2025. Prior authorization or step therapy may be required.
‡Enrollment required. Subject to terms and conditions.
Self-administration support
In-home training for patients
With in-home nurse support, a trained nurse comes to patients’ homes to make sure they’re comfortable self-infusing. Patients can virtually connect to nursing support any time they have questions throughout treatment.
Peer support
Patient advocate program
With the Patient Advocate Program, patients can stay connected to peer-to-peer support, resources, and encouragement.§
§Patient advocates are compensated by CSL Behring LLC for their time and/or expenses. The following patient experiences are based on individual accounts. Results may vary.
Reference: 1. Data on File. Available from CSL Behring as DOF HIZ-019.
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.